Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

EVOTEC : INVESTS IN EXSCIENTIA TO ADVANCE AI-DRIVEN DRUG DISCOVERY

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/28/2017 | 07:35am CET

DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC INVESTS IN EXSCIENTIA TO ADVANCE AI-DRIVEN DRUG DISCOVERY

28.09.2017 / 07:30
The issuer is solely responsible for the content of this announcement.


- EVOTEC TO INVEST EUR 15 M IN EXSCIENTIA, A PIONEER OF ARTIFICIAL INTELLIGENCE ("AI") IN DRUG DISCOVERY

- NEW FUNDS WILL ENABLE EXSCIENTIA TO ACCELERATE GROWTH

- EXPANSION OF EXISTING PARTNERSHIP TO DISCOVER NOVEL IMMUNO-ONCOLOGY THERAPEUTICS

- FIRST EVOTEC PROJECT SUPPORTED BY RECENT EUR 75 M LOAN FACILITY FROM THE EUROPEAN INVESTMENT BANK


Hamburg, Germany, Dundee, UK: 28 September 2017
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Exscientia Ltd ("Exscientia") today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia. Through this investment, Evotec becomes the first strategic shareholder in the UK-based company. Exscientia is focused on Artificial Intelligence ("AI")-driven drug discovery and design. With more than 1,800 scientists, Evotec has one of the largest and leading drug discovery platforms in the industry.

Exscientia and Evotec have cooperated since early 2016 to advance small molecules and bispecific small molecules in immuno-oncology. The ongoing success of this partnership was the basis of this expanded and deepened corporate relationship. Exscientia is the world leader in developing and applying AI approaches specifically to design new and better therapeutic molecules in a faster and more cost-effective manner. Exscientia's approach fuses the power of AI with the discovery experience of seasoned drug hunters and chemistry experts. This investment will enable Exscientia to drive higher value partner programmes and expand discovery on its automated design platform.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "Our investment in Exscientia represents Evotec's single biggest equity placement to date and in, what we feel, is the world leading AI technology company. Working with Exscientia on a joint immuno-oncology project over the past year, we have experienced first-hand how its AI approaches, along with our medicinal chemistry platform, can positively and radically impact drug discovery. We are very excited about the joint potential to leverage AI in chemistry. This investment is also the first time that we can efficiently use our recently awarded EUR 75 m loan facility from the European Investment Bank to bring down cost of capital for such an investment."

Commenting on the investment, Prof. Andrew Hopkins, Chief Executive Officer of Exscientia, added: "Exscientia and Evotec have built a close relationship over the past year sharing mutual interest in agile innovation. We are delighted that Evotec has made this investment for a minority equity stake, allowing Exscientia to deliver more drug discovery projects in a rapid and capital efficient manner. I'm also delighted that Dr Mario Polywka, Chief Operating Officer of Evotec, will join Exscientia's Board of Directors, allowing us to benefit from his strong operational expertise in growing successful biotech companies."

 

About Exscientia and AI-driven drug discovery
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

The innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds prioritised for synthesis by Exscientia's AI systems simultaneously balance potency, selectivity and pharmacokinetic criteria in order to deliver successful experimental outcomes.

By applying a rapid design-make-test cycle, the Exscientia AI system actively learns from the preceding experimental results and rapidly evolves compounds towards the desired candidate criteria. Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical companies. In addition to Evotec, partners include Sanofi (metabolic disease), Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals (CNS) and GSK. Exscientia was established as a spinout company from Prof. Andrew Hopkins laboratory at the University of Dundee.

For more information visit www.exscientia.co.uk. Follow on Twitter www.twitter.com/exscientialtd.

Media enquiries:

For Exscientia:
Mark Swallow / Sylvie Berrebi / Pip Batty - Citigate Dewe Rogerson
[email protected]; +44 207 638 9571
or
Mark Swindells - Chief Operating Officer
[email protected]

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com.

 

Contact Evotec AG:

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, [email protected]
 

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



28.09.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

613753  28.09.2017 

fncls.ssp?fn=show_t_gif&application_id=613753&application_name=news&site_id=zonebourse

© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
12/13 EVOTEC : Academic Bridge LAB282 with Oxford University celebrating one year of i..
12/13 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
12/13 EVOTEC : Enters into Research Collaboration with CRTD to Discover Novel Therapie..
12/13 EVOTEC : enters into research collaboration with CRTD to discover novel therapie..
12/12 CORRECTION OF A RELEASE FROM 11.12.2 : 40 CET/CEST - Evotec AG: Release accordin..
12/11 EVOTEC : Academic Bridge LAB282 with Oxford University Celebrating One Year of I..
12/11 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
12/11 EVOTEC : S academic bridge lab282 with oxford university celebrating one year of..
12/04 EVOTEC : receives clinical milestone as part of its discovery alliance with Boeh..
12/01 EVOTEC : Receives clinical milestone as part of its discovery alliance with boeh..
More news
News from SeekingAlpha
12/13 Evotec enters into research collaboration with CRTD to discover therapies for..
11/17 Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare Conference - Slid..
11/11 Evotec's (EVOTF) CEO Werner Lanthaler on Q3 2017 Results - Earnings Call Tran..
11/08 MY JOURNEY TO FINANCIAL INDEPENDENCE : 85-Stock October Portfolio Update - Buyin..
11/08 Evotec AG ADR 2017 Q3 - Results - Earnings Call Slides
Financials (€)
Sales 2017 246 M
EBIT 2017 46,2 M
Net income 2017 28,9 M
Debt 2017 103 M
Yield 2017 -
P/E ratio 2017 73,93
P/E ratio 2018 50,75
EV / Sales 2017 9,41x
EV / Sales 2018 7,01x
Capitalization 2 208 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,5 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG74.01%2 611
CELLTRION, INC.--.--%23 699
IQVIA HOLDINGS INC32.70%21 261
INCYTE CORPORATION-3.68%20 703
LONZA GROUP57.44%20 102
ALNYLAM PHARMACEUTICALS, INC.249.60%12 278